2024-10-01 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences is a biopharmaceutical company that develops and markets therapies for life-threatening diseases.

**Performance Analysis:**

**1. Return vs S&P 500 (VOO):**

* **Cumulative Return (GILD):** -12.61%
* **Cumulative Return (VOO):** 133.28%
* **Return Gap:** -145.89%
* **Relative Divergence:** 6.16% (This means that the stock's performance is currently in the 6.16th percentile relative to its historical performance compared to the S&P 500)

**2. Recent Price Movement:**

* **Closing Price:** $84.25
* **5-Day Moving Average:** $83.41
* **20-Day Moving Average:** $81.92
* **60-Day Moving Average:** $76.62

**3. Technical Indicators:**

* **RSI:** 72.76 (Overbought territory, indicating potential for a short-term pullback)
* **PPO:** -0.21 (Negative value suggests a bearish trend)
* **Delta_Previous_Relative_Divergence:** -0.37 (Negative value indicates short-term downward pressure)
* **Expected Return:** 0.0% (The expected return for the next 5 years is currently 0%)

**4. Recent Earnings and Forecast:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | $6.95B |
| 2024-05-08 | -3.34 | $6.69B |
| 2023-11-07 | 1.75 | $7.05B |
| 2023-08-04 | 0.84 | $6.60B |
| 2024-08-08 | 0.84 | $6.60B |

* **Most Recent Earnings:** The latest earnings for the quarter ending August 08, 2024, were $1.29 EPS and $6.95B in revenue. Analyst estimates were not available for this specific quarter.

**5. News and Recent Events:**

* **Recent Market Outlook for GILD:** Market analysts have mixed opinions on GILD's future performance. Some are optimistic about the company's pipeline of new therapies, while others are concerned about the potential for generic competition in the market.
* **Analyst Opinions and Performance Highlights:** FINBOLD reports that 14 analysts have rated GILD as a “buy”, 9 as a “hold”, and 1 as a “sell”. The average target price is $92.60.

**6. Overall Analysis:**

Gilead Sciences is currently facing a challenging market environment, with its stock price lagging behind the S&P 500. Technical indicators suggest a potential for a short-term pullback, with the RSI indicating overbought territory. While the recent earnings report was positive, there are concerns about the company's future growth prospects and the potential for generic competition. Analysts have mixed opinions, with some expressing optimism about the company's pipeline while others are more cautious. Investors should closely monitor Gilead's progress in developing new therapies and the competitive landscape before making any investment decisions. 

**7. Conclusion:**

Overall, Gilead Sciences is a company with a strong track record and a robust pipeline of new therapies. However, the current market environment and the potential for generic competition pose challenges to the company's future growth prospects. Investors should carefully consider these factors before making any investment decisions. 
